PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcpsycBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Psychiatry
 
BMC Psychiatry. 2011; 11: 145.
Published online Aug 31, 2011. doi:  10.1186/1471-244X-11-145
PMCID: PMC3178484
Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial
Eirik Kjelby,corresponding author1 Hugo A Jørgensen,2 Rune A Kroken,1 Else-Marie Løberg,1,3 and Erik Johnsen1,2
1Division of Psychiatry, Haukeland University Hospital, Sandviken, Norway
2Department of Clinical Medicine, Psychiatry, University of Bergen, Norway
3University of Bergen, Inst. Biological and Medical Psychology, Norway
corresponding authorCorresponding author.
Eirik Kjelby: eirik.kjelby/at/helse-bergen.no; Hugo A Jørgensen: hugo.jorgensen/at/kliniskmedisin.uib.no; Rune A Kroken: rune.kroken/at/helse-bergen.no; Else-Marie Løberg: Else.Marie.Loeberg/at/psych.uib.no; Erik Johnsen: erij/at/helse-bergen.no
Received February 18, 2011; Accepted August 31, 2011.
Abstract
Background
Efficacy studies indicate anti-depressive effects of at least some second generation antipsychotics (SGAs). The Bergen Psychosis Project (BPP) is a 24-month, pragmatic, industry-independent, randomized, head-to-head comparison of olanzapine, quetiapine, risperidone and ziprasidone in patients acutely admitted with psychosis. The aim of the study is to investigate whether differential anti-depressive effectiveness exists among SGAs in a clinically relevant sample of patients acutely admitted with psychosis.
Methods
Adult patients acutely admitted to an emergency ward for psychosis were randomized to olanzapine, quetiapine, risperidone or ziprasidone and followed for up to 2 years. Participants were assessed repeatedly using the Positive and Negative Syndrome Scale - Depression factor (PANSS-D) and the Calgary Depression Scale for Schizophrenia (CDSS).
Results
A total of 226 patients were included. A significant time-effect showing a steady decline in depressive symptoms in all medication groups was demonstrated. There were no substantial differences among the SGAs in reducing the PANSS-D score or the CDSS sum score. Separate analyses of groups with CDSS sum scores > 6 or ≤6, respectively, reflecting degree of depressive morbidity, revealed essentially identical results to the primary analyses. There was a high correlation between the PANSS-D and the CDSS sum score (r = 0.77; p < 0.01).
Conclusions
There was no substantial difference in anti-depressive effectiveness among olanzapine, quetiapine, risperidone or ziprasidone in this clinically relevant sample of patients acutely admitted to hospital for symptoms of psychosis. Based on our findings we can make no recommendations concerning choice of any particular SGA for targeting symptoms of depression in a patient acutely admitted with psychosis.
Trial Registration
ClinicalTrials.gov ID; URL: http://www.clinicaltrials.gov/: NCT00932529
Articles from BMC Psychiatry are provided here courtesy of
BioMed Central